A705of ischemic stroke moderate and severe degrees of severity using a drug cerebrolysin compared with standard therapy, cost-effectiveness ratios (CER) were obtained 419656 RUB (6920 EUR) and 563183 RUB (9287 EUR), respectively. ConClusions: The standard therapy in combination with drug cerebrolysin has a lower CER compared with standard therapy, therefore, it is a dominant technology from the perspective of the cost-effectiveness analysis.

No abstract

No abstract

A69932.5% oncology, 17.5% auto-immune, 15% cardiovascular, 10% neurology/mental health, 5% infectious, 5% diabetes, and 15% other. Modeling techniques included discrete event simulation (12%), individual state-transition (15%) and most commonly state transition with tracking states. In most cases treatment sequencing was modeled to reflect clinical practice or clinical trial design. Other reasons included assessing where in a treatment sequence the new treatment belongs or evaluating the addition of more efficacious treatment options to the current treatment sequence. Efficacy inputs were generally based on trials that considered a single intervention and not a treatment sequence. Efficacy was commonly assumed to be the same regardless of line of therapy. Disease-related costs and utilities were mostly determined by disease status or its related events, and only seldomly by line of therapy. ConClusions: Capturing treatment sequences in economic models is important for informing reimbursement, policy and clinical decisions. Key considerations for determining how to best model sequences include: the number of treatment options, patient heterogeneity, key outcome events and event risk (time-varying or constant). A key challenge to model treatment sequences is the scarcity of the clinical data as clinical trials do not commonly study sequences. PRM95 Budget IMPact analysIs of ceReBRolysIn In the tReatMent of acute IscheMIc stRoke of ModeRate and seveRe degRees of seveRIty In the RussIan fedeRatIon

Objectives: To analyze the cost of illness in the management of anemia among chronic kidney disease (CKD) patients on hemodialysis MethOds: Prospective observational study for a period 7 months was conducted after the approval of the protocol by the Ethics Committee. The patients on hemodialysis of both sexes aged between 18-75 years were enrolled in the management of anemia with erythropoietin (EPO). The data relating to the cost and the number of units for EPO, Iron and Vitamin supplements were recorded and computed on weekly basis. Hemoglobin levels were recorded every month. The average cost incurred was calculated for 7 months. Results: The number of subjects included in the study was 62 out of 96 patients. The total number of EPO administered for 7 months was computed by adding all the doses for 7 months. On an average, each subject was administered 27.44 of EPO doses equivalent to 113001.35 IU. The Iron supplements and vitamins constituted 15.54 doses and 32.6 doses respectively. The response of above-mentioned treatment reflected in raise in 8.67 g/dl hemoglobin levels per patient per 7 months. The cost of EPO for doses administered was 111859.92 INR (1864.32 USD), Iron supplements 5594.4 INR (93.24 USD), Vitamin supplements 1587.83 INR (26.46 USD). In addition, the laboratory charges for the measurement of hemoglobin levels were 325 INR (5.41 USD) per patient per 7 months. cOnclusiOns: Study reveals 64.58% of patients were economically sound to undergo the treatment with EPO. Eighteen patients were covered by Employees' State Insurance and 2 patients supported by their employers on reimbursement basis and the remaining 40 patients borne the expenses by themselves. The study revealed that the average cost in the management of anemia among chronic kidney disease patients on hemodialysis per patient per 7 months was 119367.15 INR (1989.45 USD).